Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Century Therapeutics (IPSC) has 3 years of Current Deferred Revenue data on file, last reported at $109.2 million in Q4 2024.

• Current Deferred Revenue for Q4 2024 came in at $109.2 million, up 2396.89% year-over-year; the trailing twelve-month figure through Dec 2024 was $109.2 million (up 2396.89% YoY), and the FY2024 annual result was $109.2 million, up 2396.89% from the prior year.
• Current Deferred Revenue rose to $109.2 million in Q4 2024 per IPSC's latest filing, from $3.6 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $109.2 million in Q4 2024 and troughed at $3.6 million in Q3 2024.
• A 3-year average of $14.4 million and a median of $6.4 million in 2022 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue plunged 48.87% in 2023, then surged 2396.89% in 2024.
• A 3-year view of Current Deferred Revenue shows it stood at $7.2 million in 2022, then tumbled by 38.89% to $4.4 million in 2023, then surged by 2396.89% to $109.2 million in 2024.
• Business Quant data shows IPSC's Current Deferred Revenue at $109.2 million in Q4 2024, $3.6 million in Q3 2024, and $4.4 million in Q2 2024.